Immix Biopharma Investor Presentation Deck
IMMIX Biopharma Investment Highlights
1
2
3
4
LO
5
NXC-201 - First CAR-T in AL
Amyloidosis
Addressing shortage of
multiple myeloma CAR-Ts
First CAR-T Overcoming
Neurotoxicity
NXC-201 n=72 patients
9 peer-reviewed publications
IMX-110 - promising results in
colorectal cancer with 30
patients dosed
.
100% overall response rate in relapsed/refractory AL amyloidosis ($3bn market)
No drugs approved in relapsed/refractory AL amyloidosis today
95% overall response rate in relapsed/refractory multiple myeloma ($18bn market)
75% of patients on multiple myeloma CAR-T waiting lists do not receive the CAR-T therapy
-10-20x potential increase in CAR-T addressable market through wider hospital availability
~5x potential hospital per-bed revenue increase by reducing CAR-T hospitalization time
Overcoming neurotoxicity allows expansion into: AL Amyloidosis, autoimmune, others
●●●
IMMIX
S BIOPHARMA
Mature dataset: American Society of Cell and Gene Therapy, Haematologica, other publications
Precedents for open-label, single-arm FDA approvals at ~100 patient dataset - Carvykti, Abecma
75% tumor shrinkage at 2 months in stage 4 MSS relapsed/refractory colorectal cancer ($27 billion market)
4 months median progression-free survival in soft tissue sarcoma ($3bn market), median 7 prior lines of therapy
36View entire presentation